EVALUATION OF ANXIOLYTIC THERAPY FOR THE ANTICIPATORY NAUSEA AND/OR VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY (LORAZEPAM)
Abstract
Patients receiving cancer chemotherapy were entered into a randomized, placebo-controlled, double-blind study to evaluate the effectiveness of orally administered lorazepam (given the evening before and the morning of scheduled treatment) on chemotherapy associated anxiety and sickness. In addition to demographic information, the following self-report instruments were utilized to gather data: Morrow Assessment of Nausea and Emesis; Multiple Affect Adjective Check List; and 100 mm visual analogue scales for nausea, vomiting, sleepiness, and anxiety. Within the limits of this study, orally administered lorazepam was not found to be more effective than placebo in reducing chemotherapy associated anxiety and sickness. Significant toxicity was seen in the patients randomized to lorazepam, one third of the patients being withdrawn from the study due to excessive sedation or disorientation.
Degree
Ph.D.
Subject Area
Pharmaceuticals
Off-Campus Purdue Users:
To access this dissertation, please log in to our
proxy server.